Infective EndocarditisObservatoireEINCT03272724
French National Observatory on Infective Endocarditis
An observational study of Infective Endocarditis, run by Central Hospital, Nancy, France at 1 site in France.
Trial summary
The objective of this observatory is to provide a national database of infective endocarditis, informed by all volunteer centers, using a standardized case report forms. Such an observatory will describe the clinical profile, microbiological, therapeutic and evolving of infective endocarditis (IE); analyze the risk… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Infective Endocarditis
- How many people
- 5,000 participants
- Where
- 1 siteFrance
- Study dates
- 1 Jan 1991to 31 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult hospitalized patients, suspected of infective endocarditis
Who may be able to join
- Major Patient
- Supported in one of the participating centers
- The application of diagnostic classification criteria of Duke modified by Li is carried out after collection of all the data at the end of the patient's hospitalization. Only patients meeting criteria for definite or possible endocarditis will be included in the analyses.
- Registered with the French social security system
Who cannot join
- Refusal of the patient to participate.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Nadine JUGE, PhD contact
France1 site, 1 recruiting
- Recruiting
CHRU
Vandœuvre-lès-Nancy, 54511
Christine SELTON-SUTY, MD, c.suty-selton@chru-nancy.fr
About this study
The objective of this observatory is to provide a national database of infective endocarditis, informed by all volunteer centers, using a standardized case report forms.
Such an observatory will describe the clinical profile, microbiological, therapeutic and evolving of infective endocarditis (IE); analyze the risk factors for the disease and its prognosis factors of evolution; describe management practices; evaluate and compare in the real drug treatment strategies (including antibiotics) and surgical.
Read the detailed description
All the clinical, biological, microbiological and laboratory describing the history of patients and their evolution during hospitalization for infective endocarditis will be obtained from physicians supporting patients and recorded in an electronic case report form. Will include collected clinical characteristics (site, pre-existing heart disease underlying symptoms, complications), biological characteristics (dosage on admission and diagnosis), microbiological characteristics (identifying the genus and species of the microorganism responsible, sensitivity to antibiotics susceptibility testing and evaluated by determination of minimal inhibiting concentration (MIC), exhaustive search of the rare forms of endocarditis uncultivated microorganisms), an analysis of the gateways based on the causative organism; echocardiographic characteristics (number and size of vegetations, valvular damage, scalable: surgery, lethality) and therapeutic characteristics (antibiotic treatment, surgical).
- Conditions
- Infective Endocarditis
- Medical subject headings
- Endocarditis
What is being measured
The primary outcome is the main question the study is designed to answer.
history of heart disease
status of heart valves, pre-existing heart conditions
Measured: inclusion
risk factors, medical history
associated diseases
Measured: inclusion
origin of infection
high risk procedures
Measured: period of 3 months before infective endocarditis
weight
kg
Measured: inclusion
height
cm
Measured: inclusion
clinical symptoms
cardiac, peripheral and neurological symptoms
Measured: inclusion
biological outcomes
blood count
Measured: inclusion
microbiological outcomes
identification of infecting organisms
Measured: inclusion
diagnostic imaging
description of tyhe imaging tests performed
Measured: inclusion
antibiotic therapy
antibiotic treatment: type and duration
Measured: from inclusion to recovery
surgical procedures
description of surgical procedures
Measured: from inclusion to recovery
Secondary outcomes (1)
biologic collection (optional)
plasma and serum collection
Measured: inclusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Sep 2017
- Study start1 Jan 1991
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (17)Papers the sponsor has linked to this study.
- Other trials for Infective EndocarditisStudies of the same condition, open and under way.
- More trials run by Central Hospital, Nancy, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 5,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Central Hospital, Nancy, France
- Sponsor type
- University, hospital or other
- Collaborators
- Bichat Hospital, Centre Hospitalier Universitaire de la Guadeloupe, Centre Hospitalier Universitaire de Besancon, Hospices Civils de Lyon, University Hospital, Montpellier, Rennes University Hospital, Hôpital Saint André, Reims, Henri Mondor University Hospital, Polyclinique Courlancy, Reims, Centre Hospitalier Universitaire de Saint Etienne, Bicetre Hospital, Centre Hospitalier Universitaire, Amiens, Centre Hospitalier Universitaire Dijon, Centre Hospitalier Annecy Genevois, Centre Hospitalier de Roanne, Centre hospitalier Pierre Oudot Bourgoin-Jallieu, L'hôpital Nord-Ouest - Villefranche Villefranche sur Saône, Hôpital d'Instruction des Armées Desgenettes, Hôpital intercommunal Sud Léman Valserine, Saint Julien en Genevois, University Hospital, Grenoble, Centre Cardiologique du Nord, Centre Hospitalier Intercommunal Robert Ballanger, Raincy Montfermeil Hospital Group, Pitié-Salpêtrière Hospital, Hôpital Cochin, Hospital Avicenne, Beaujon Hospital, European Georges Pompidou Hospital, Hopital Foch, Hotel Dieu Hospital, Hôpital Jean Verdier, Hopital Lariboisière, Hôpital Necker-Enfants Malades, Fondation Hôpital Saint-Joseph, Saint-Louis Hospital, Paris, France, Tenon Hospital, Paris, Saint Antoine University Hospital, Centre hospitalier de Saint Dié des Vosges, Centre Hospitalier Régional Metz-Thionville, Hôpital d'Instruction des Armées Legouest, Hôpital sainte Blandine Metz, Hôpital-clinique Claude Bernard, Metz, Polyclinique Louis Pasteur Essey-les-Nancy, Hopital Nord Franche-Comte, Lons le Saunier hospital, Pontarlier hospital, Epernay hospital, Chalons en Champagne hospital, Clinique Saint Vincent Epernay, Hôpital Maison Blanche Reims, Hopital Universitaire Robert-Debre, Beziers Hospital, Louis Pasteur hospital, Bagnols sur Cèze, Perpignan Hospital Center, Narbonne Hospital, Clinique du Millenaire, Centre Hospitalier Universitaire de Nīmes, Saint Malo hospital, HIA Begin, Saint Mandé, Centre Hospitalier d'Alès-Cévennes, University Hospital, Bordeaux, Centre hospitalier de Chambéry, Poitiers University Hospital, Centre Hospitalier Intercommunal Villeneuve Saint Georges, Centre Hospitalier Argenteuil, Hospital St. Joseph, Marseille, France, Centre hospitalier de Vannes, University Hospital, Strasbourg, France, Centre Hospitalier Régional d'Orléans
- Responsible party
- Principal investigator, Christine Selton-Suty, Central Hospital, Nancy, France
- Investigators
- Christine SELTON-SUTY, MD, Principal investigator, CHRU Nancy
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03272724
- Sponsor's protocol ID
- Observatoire EI
- Acronym
- ObservatoireEI
- Status last verified
- Sep 2025
- First submitted
- 28 Aug 2017
- Last updated
- 23 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Lefevre B, Habib G, Hoen B, Selton-Suty C, Philip M, Issa N, Danneels P, De La Chapelle M, Deschanvres C, Erpelding ML, Tattevin P, Le Bot A, Villamarin M, Fernandez-Hidalgo N, Tribouilloy C, Pluquet E, Dubee V, Hannan M, Dornikova G, Durante-Mangoni E, Bertolino L, Siciliano RF, Amaral de Oliveira AM, Goulart Correia M, Gouriet F, Lamas C. Staphylococcus lugdunensis infective endocarditis: a multicentre international observational study. Infect Dis (Lond). 2026 Feb;58(2):189-197. doi: 10.1080/23744235.2025.2556921. Epub 2025 Sep 15.
PubMed 40952378Selton-Suty C, Goehringer F, Venner C, Thivilier C, Huttin O, Hoen B; membres de l'Endocarditis Team du CHU de Nancy. [Complications and prognosis of infective endocarditis]. Presse Med. 2019 May;48(5):532-538. doi: 10.1016/j.lpm.2019.04.002. Epub 2019 May 2. French.
PubMed 31056233Hoen B, Elfarra M, Huttin O, Goehringer F, Venner C, Selton-Suty C; l'Endocarditis Team du CHU de Nancy. [Treatment of infectious endocarditis]. Presse Med. 2019 May;48(5):539-548. doi: 10.1016/j.lpm.2019.04.015. Epub 2019 May 18. French.
PubMed 31109766N'Guyen Y, Duval X, Revest M, Saada M, Erpelding ML, Selton-Suty C, Bouchiat C, Delahaye F, Chirouze C, Alla F, Strady C, Hoen B; AEPEI study group. Time interval between infective endocarditis first symptoms and diagnosis: relationship to infective endocarditis characteristics, microorganisms and prognosis. Ann Med. 2017 Mar;49(2):117-125. doi: 10.1080/07853890.2016.1235282. Epub 2016 Nov 3.
PubMed 27607562Lefevre B, Hoen B, Goehringer F, Sime WN, Aissa N, Alauzet C, Jeanmaire E, Henard S, Filippetti L, Selton-Suty C, Agrinier N; for AEPEI study group (Association pour l'Etude et la Prevention de l'Endocardite Infectieuse). Antistaphylococcal penicillins vs. cefazolin in the treatment of methicillin-susceptible Staphylococcus aureus infective endocarditis: a quasi-experimental monocentre study. Eur J Clin Microbiol Infect Dis. 2021 Dec;40(12):2605-2616. doi: 10.1007/s10096-021-04313-3. Epub 2021 Aug 12.
PubMed 34383175Collonnaz M, Erpelding ML, Alla F, Goehringer F, Delahaye F, Iung B, Le Moing V, Hoen B, Selton-Suty C, Agrinier N; AEPEI Study Group. Impact of referral bias on prognostic studies outcomes: insights from a population-based cohort study on infective endocarditis. Ann Epidemiol. 2021 Feb;54:29-37. doi: 10.1016/j.annepidem.2020.09.008. Epub 2020 Sep 18.
PubMed 32950657Collonnaz M, Erpelding ML, Alla F, Goehringer F, Delahaye F, Iung B, Le Moing V, Hoen B, Selton-Suty C, Agrinier N; AEPEI study group. Data on prognostic factors associated with 3-month and 1-year mortality from infective endocarditis. Data Brief. 2020 Nov 1;33:106478. doi: 10.1016/j.dib.2020.106478. eCollection 2020 Dec.
PubMed 33225027De Ciancio G, Erpelding ML, Filippetti L, Goehringer F, Blangy H, Huttin O, Agrinier N, Juilliere Y, Sadoul N, Selton-Suty C. Adherence to diagnostic and therapeutic practice guidelines for suspected cardiac implantable electronic device infections. Arch Cardiovasc Dis. 2021 Oct;114(10):634-646. doi: 10.1016/j.acvd.2021.06.010. Epub 2021 Nov 3.
PubMed 34742672Selton-Suty C, Delahaye F, Tattevin P, Federspiel C, Le Moing V, Chirouze C, Nazeyrollas P, Vernet-Garnier V, Bernard Y, Chocron S, Obadia JF, Alla F, Hoen B, Duval X; AEPEI (Association pour l'Etude et la Prevention de l'Endocardite Infectieuse). Symptomatic and Asymptomatic Neurological Complications of Infective Endocarditis: Impact on Surgical Management and Prognosis. PLoS One. 2016 Jul 11;11(7):e0158522. doi: 10.1371/journal.pone.0158522. eCollection 2016.
PubMed 27400273Radjabaly Mandjee A, Filippetti L, Goehringer F, Duval X, Botelho-Nevers E, Tribouilloy C, Huguet R, Chirouze C, Erpelding ML, Hoen B, Selton-Suty C, Agrinier N, Lefevre B; investigators of the French AEPEI Observatory on Infective Endocarditis (Association pour l'Etude et la Prevention de l'Endocardite Infectieuse). Characteristics of patients with infective endocarditis and no underlying cardiac conditions. Infect Dis (Lond). 2022 Sep;54(9):656-665. doi: 10.1080/23744235.2022.2078404. Epub 2022 May 23.
PubMed 35604065Beraud G, Tubiana S, Erpelding ML, Le Moing V, Chirouze C, Gorenne I, Manchon P, Tattevin P, Vernet V, Varon E, Hoen B, Duval X; AEPEI study group; COMBAT study group. Combined Bacterial Meningitis and Infective Endocarditis: When Should We Search for the Other When Either One is Diagnosed? Infect Dis Ther. 2022 Aug;11(4):1521-1540. doi: 10.1007/s40121-022-00651-7. Epub 2022 May 26.
PubMed 35618954Lefevre B, Legoff A, Boutrou M, Goehringer F, Ngueyon-Sime W, Chirouze C, Revest M, Vernet Garnier V, Duval X, Delahaye F, Le Moing V, Selton-Suty C, Filippetti L, Hoen B, Agrinier N. Staphylococcus aureus endocarditis: Identifying prognostic factors using a method derived from morbidity and mortality conferences. Front Med (Lausanne). 2022 Dec 6;9:1053278. doi: 10.3389/fmed.2022.1053278. eCollection 2022.
PubMed 36561723Fowler VG, Durack DT, Selton-Suty C, Athan E, Bayer AS, Chamis AL, Dahl A, DiBernardo L, Durante-Mangoni E, Duval X, Fortes CQ, Fosbol E, Hannan MM, Hasse B, Hoen B, Karchmer AW, Mestres CA, Petti CA, Pizzi MN, Preston SD, Roque A, Vandenesch F, van der Meer JTM, van der Vaart TW, Miro JM. The 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis: Updating the Modified Duke Criteria. Clin Infect Dis. 2023 Aug 22;77(4):518-526. doi: 10.1093/cid/ciad271.
PubMed 37138445El Hatimi S, Erpelding ML, Selton-Suty C, Botros JB, Goehringer F, Berthelot E, Elfarra M, Deconinck L, Para M, Provenchere S, Hoen B, Agrinier N, Duval X, Iung B. Predictive performance of surgical mortality risk scores in infective endocarditis. Eur J Cardiothorac Surg. 2024 Jan 2;65(1):ezad433. doi: 10.1093/ejcts/ezad433.
PubMed 38175782Bucy L, Erpelding ML, Boursier C, Lefevre B, Alauzet C, Liu Y, Chevalier E, Huttin O, Agrinier N, Selton-Suty C, Goehringer F; AEPEI study group (Association pour l'Etude et la Prevention de l'Endocardite Infectieuse). Real world experience of therapeutic monitoring of medically treated prosthetic valve infective endocarditis by 18F-FDG-PET/CT. J Nucl Cardiol. 2023 Oct;30(5):2096-2103. doi: 10.1007/s12350-023-03339-8. Epub 2023 Jul 31.
PubMed 37524996
Study at a glance
From the registry record, last updated by the sponsor on 23 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- French National Observatory on Infective Endocarditis
- ClinicalTrials.gov ID
- NCT03272724
- Acronym / sponsor ID
- ObservatoireEI / Observatoire EI
- Conditions
- Infective Endocarditis
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 5,000 participants (estimated)
- Lead sponsor
- Central Hospital, Nancy, FranceUniversity, hospital or other
- Collaborators
- Bichat Hospital, Centre Hospitalier Universitaire de la Guadeloupe, Centre Hospitalier Universitaire de Besancon, Hospices Civils de Lyon, University Hospital, Montpellier, Rennes University Hospital, Hôpital Saint André, Reims, Henri Mondor University Hospital, Polyclinique Courlancy, Reims, Centre Hospitalier Universitaire de Saint Etienne, Bicetre Hospital, Centre Hospitalier Universitaire, Amiens, Centre Hospitalier Universitaire Dijon, Centre Hospitalier Annecy Genevois, Centre Hospitalier de Roanne, Centre hospitalier Pierre Oudot Bourgoin-Jallieu, L'hôpital Nord-Ouest - Villefranche Villefranche sur Saône, Hôpital d'Instruction des Armées Desgenettes, Hôpital intercommunal Sud Léman Valserine, Saint Julien en Genevois, University Hospital, Grenoble, Centre Cardiologique du Nord, Centre Hospitalier Intercommunal Robert Ballanger, Raincy Montfermeil Hospital Group, Pitié-Salpêtrière Hospital, Hôpital Cochin, Hospital Avicenne, Beaujon Hospital, European Georges Pompidou Hospital, Hopital Foch, Hotel Dieu Hospital, Hôpital Jean Verdier, Hopital Lariboisière, Hôpital Necker-Enfants Malades, Fondation Hôpital Saint-Joseph, Saint-Louis Hospital, Paris, France, Tenon Hospital, Paris, Saint Antoine University Hospital, Centre hospitalier de Saint Dié des Vosges, Centre Hospitalier Régional Metz-Thionville, Hôpital d'Instruction des Armées Legouest, Hôpital sainte Blandine Metz, Hôpital-clinique Claude Bernard, Metz, Polyclinique Louis Pasteur Essey-les-Nancy, Hopital Nord Franche-Comte, Lons le Saunier hospital, Pontarlier hospital, Epernay hospital, Chalons en Champagne hospital, Clinique Saint Vincent Epernay, Hôpital Maison Blanche Reims, Hopital Universitaire Robert-Debre, Beziers Hospital, Louis Pasteur hospital, Bagnols sur Cèze, Perpignan Hospital Center, Narbonne Hospital, Clinique du Millenaire, Centre Hospitalier Universitaire de Nīmes, Saint Malo hospital, HIA Begin, Saint Mandé, Centre Hospitalier d'Alès-Cévennes, University Hospital, Bordeaux, Centre hospitalier de Chambéry, Poitiers University Hospital, Centre Hospitalier Intercommunal Villeneuve Saint Georges, Centre Hospitalier Argenteuil, Hospital St. Joseph, Marseille, France, Centre hospitalier de Vannes, University Hospital, Strasbourg, France, Centre Hospitalier Régional d'Orléans
- Study start
- 1 Jan 1991 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 6 Sep 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this observatory is to provide a national database of infective endocarditis, informed by all volunteer centers, using a standardized case report forms.
Such an observatory will describe the clinical profile, microbiological, therapeutic and evolving of infective endocarditis (IE); analyze the risk factors for the disease and its prognosis factors of evolution; describe management practices; evaluate and compare in the real drug treatment strategies (including antibiotics) and surgical.
Detailed description
All the clinical, biological, microbiological and laboratory describing the history of patients and their evolution during hospitalization for infective endocarditis will be obtained from physicians supporting patients and recorded in an electronic case report form. Will include collected clinical characteristics (site, pre-existing heart disease underlying symptoms, complications), biological characteristics (dosage on admission and diagnosis), microbiological characteristics (identifying the genus and species of the microorganism responsible, sensitivity to antibiotics susceptibility testing and evaluated by determination of minimal inhibiting concentration (MIC), exhaustive search of the rare forms of endocarditis uncultivated microorganisms), an analysis of the gateways based on the causative organism; echocardiographic characteristics (number and size of vegetations, valvular damage, scalable: surgery, lethality) and therapeutic characteristics (antibiotic treatment, surgical).
Study design
- Observational model
- Cohort
- Time perspective
- Other
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult hospitalized patients, suspected of infective endocarditis
Key inclusion criteria (4 listed)
- Major Patient
- Supported in one of the participating centers
- The application of diagnostic classification criteria of Duke modified by Li is carried out after collection of all the data at the end of the patient's hospitalization. Only patients meeting criteria for definite or possible endocarditis will be included in the analyses.
- Registered with the French social security system
Key exclusion criteria (1 listed)
- Refusal of the patient to participate.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
history of heart disease
Time frame: inclusion
status of heart valves, pre-existing heart conditions
risk factors, medical history
Time frame: inclusion
associated diseases
origin of infection
Time frame: period of 3 months before infective endocarditis
high risk procedures
weight
Time frame: inclusion
kg
height
Time frame: inclusion
cm
clinical symptoms
Time frame: inclusion
cardiac, peripheral and neurological symptoms
biological outcomes
Time frame: inclusion
blood count
microbiological outcomes
Time frame: inclusion
identification of infecting organisms
diagnostic imaging
Time frame: inclusion
description of tyhe imaging tests performed
antibiotic therapy
Time frame: from inclusion to recovery
antibiotic treatment: type and duration
surgical procedures
Time frame: from inclusion to recovery
description of surgical procedures
1 secondary outcome
biologic collection (optional)
Time frame: inclusion
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Sep 2025.
- Results publication: PubMed 40952378Lefevre B, Habib G, Hoen B, Selton-Suty C, Philip M, Issa N, Danneels P, De La Chapelle M, Deschanvres C, Erpelding ML, Tattevin P, Le Bot A, Villamarin M, Fernandez-Hidalgo N, Tribouilloy C, Pluquet E, Dubee V, Hannan M, Dornikova G, Durante-Mangoni E, Bertolino L, Siciliano RF, Amaral de Oliveira AM, Goulart Correia M, Gouriet F, Lamas C. Staphylococcus lugdunensis infective endocarditis: a multicentre international observational study. Infect Dis (Lond). 2026 Feb;58(2):189-197. doi: 10.1080/23744235.2025.2556921. Epub 2025 Sep 15.
- Results publication: PubMed 31056233Selton-Suty C, Goehringer F, Venner C, Thivilier C, Huttin O, Hoen B; membres de l'Endocarditis Team du CHU de Nancy. [Complications and prognosis of infective endocarditis]. Presse Med. 2019 May;48(5):532-538. doi: 10.1016/j.lpm.2019.04.002. Epub 2019 May 2. French.
- Results publication: PubMed 31109766Hoen B, Elfarra M, Huttin O, Goehringer F, Venner C, Selton-Suty C; l'Endocarditis Team du CHU de Nancy. [Treatment of infectious endocarditis]. Presse Med. 2019 May;48(5):539-548. doi: 10.1016/j.lpm.2019.04.015. Epub 2019 May 18. French.
- Results publication: PubMed 27607562N'Guyen Y, Duval X, Revest M, Saada M, Erpelding ML, Selton-Suty C, Bouchiat C, Delahaye F, Chirouze C, Alla F, Strady C, Hoen B; AEPEI study group. Time interval between infective endocarditis first symptoms and diagnosis: relationship to infective endocarditis characteristics, microorganisms and prognosis. Ann Med. 2017 Mar;49(2):117-125. doi: 10.1080/07853890.2016.1235282. Epub 2016 Nov 3.
- Results publication: PubMed 34383175Lefevre B, Hoen B, Goehringer F, Sime WN, Aissa N, Alauzet C, Jeanmaire E, Henard S, Filippetti L, Selton-Suty C, Agrinier N; for AEPEI study group (Association pour l'Etude et la Prevention de l'Endocardite Infectieuse). Antistaphylococcal penicillins vs. cefazolin in the treatment of methicillin-susceptible Staphylococcus aureus infective endocarditis: a quasi-experimental monocentre study. Eur J Clin Microbiol Infect Dis. 2021 Dec;40(12):2605-2616. doi: 10.1007/s10096-021-04313-3. Epub 2021 Aug 12.
- Results publication: PubMed 32950657Collonnaz M, Erpelding ML, Alla F, Goehringer F, Delahaye F, Iung B, Le Moing V, Hoen B, Selton-Suty C, Agrinier N; AEPEI Study Group. Impact of referral bias on prognostic studies outcomes: insights from a population-based cohort study on infective endocarditis. Ann Epidemiol. 2021 Feb;54:29-37. doi: 10.1016/j.annepidem.2020.09.008. Epub 2020 Sep 18.
- Results publication: PubMed 33225027Collonnaz M, Erpelding ML, Alla F, Goehringer F, Delahaye F, Iung B, Le Moing V, Hoen B, Selton-Suty C, Agrinier N; AEPEI study group. Data on prognostic factors associated with 3-month and 1-year mortality from infective endocarditis. Data Brief. 2020 Nov 1;33:106478. doi: 10.1016/j.dib.2020.106478. eCollection 2020 Dec.
- Results publication: PubMed 34742672De Ciancio G, Erpelding ML, Filippetti L, Goehringer F, Blangy H, Huttin O, Agrinier N, Juilliere Y, Sadoul N, Selton-Suty C. Adherence to diagnostic and therapeutic practice guidelines for suspected cardiac implantable electronic device infections. Arch Cardiovasc Dis. 2021 Oct;114(10):634-646. doi: 10.1016/j.acvd.2021.06.010. Epub 2021 Nov 3.
- Results publication: PubMed 27400273Selton-Suty C, Delahaye F, Tattevin P, Federspiel C, Le Moing V, Chirouze C, Nazeyrollas P, Vernet-Garnier V, Bernard Y, Chocron S, Obadia JF, Alla F, Hoen B, Duval X; AEPEI (Association pour l'Etude et la Prevention de l'Endocardite Infectieuse). Symptomatic and Asymptomatic Neurological Complications of Infective Endocarditis: Impact on Surgical Management and Prognosis. PLoS One. 2016 Jul 11;11(7):e0158522. doi: 10.1371/journal.pone.0158522. eCollection 2016.
- Results publication: PubMed 35604065Radjabaly Mandjee A, Filippetti L, Goehringer F, Duval X, Botelho-Nevers E, Tribouilloy C, Huguet R, Chirouze C, Erpelding ML, Hoen B, Selton-Suty C, Agrinier N, Lefevre B; investigators of the French AEPEI Observatory on Infective Endocarditis (Association pour l'Etude et la Prevention de l'Endocardite Infectieuse). Characteristics of patients with infective endocarditis and no underlying cardiac conditions. Infect Dis (Lond). 2022 Sep;54(9):656-665. doi: 10.1080/23744235.2022.2078404. Epub 2022 May 23.
- Results publication: PubMed 35618954Beraud G, Tubiana S, Erpelding ML, Le Moing V, Chirouze C, Gorenne I, Manchon P, Tattevin P, Vernet V, Varon E, Hoen B, Duval X; AEPEI study group; COMBAT study group. Combined Bacterial Meningitis and Infective Endocarditis: When Should We Search for the Other When Either One is Diagnosed? Infect Dis Ther. 2022 Aug;11(4):1521-1540. doi: 10.1007/s40121-022-00651-7. Epub 2022 May 26.
- Results publication: PubMed 36561723Lefevre B, Legoff A, Boutrou M, Goehringer F, Ngueyon-Sime W, Chirouze C, Revest M, Vernet Garnier V, Duval X, Delahaye F, Le Moing V, Selton-Suty C, Filippetti L, Hoen B, Agrinier N. Staphylococcus aureus endocarditis: Identifying prognostic factors using a method derived from morbidity and mortality conferences. Front Med (Lausanne). 2022 Dec 6;9:1053278. doi: 10.3389/fmed.2022.1053278. eCollection 2022.
- Individual participant dataSharing planned: No
Related trials for Infective Endocarditis
Not yet recruiting
Metabolic Profiling Among Patients Suspected of Infective Endocarditis - PPSIE Comparing Metabolomes of Bloodstream Infections Versus Infective Endocarditis
Infective Endocarditis (IE)
Recruiting
CBCT vs OPT on the Oral Health Status at 12 Months of Patients Hospitalized for Infective Endocarditis.
Infective Endocarditis
RecruitingObservational study
Impact of Preoperative Dental Screening in Reducing Infective Endocarditis Risk in Transcatheter Aortic Valve Implantation Patients
Transcatheter Aortic Valve Implantation, Dental
RecruitingPhase 3
Rifampin-free Regimen Versus Rifampin-containing Regimen in the Treatment of Staphylococcal Prosthetic Valve Endocarditis
Infective Endocarditis
Not yet recruitingObservational study
AngioVac Aspiration Therapy Registry
Intracardiac Thrombus, Intracardiac Mass
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Nadine JUGE, PhD contact
Christine SELTON-SUTY, MD principal investigator
CHRU Nancy
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Infective Endocarditis, run by Central Hospital, Nancy, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Nadine JUGE, PhD (n.juge@chru-nancy.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
history of heart disease (time frame: inclusion). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03272724, which also lists 17 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2025.